Available data suggest that younger age is an independent risk factor for disease recurrence and death in women with breast cancer. However, there has not been adequate study of the interaction of age with human epidermal growth factor receptor 2 (HER2) status or anti-HER2 treatment. In an analysis ...
A large prospective multicenter cohort study in France and Belgium, reported by the Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique, has shown that critically ill patients with hematologic malignancies admitted to the intensive care unit (ICU) have good survival,...
A study examining trends in x-ray computed tomography (CT) use in children in the United States has found that reducing unnecessary scans and lowering the doses for the highest-dose scans could lower the overall lifetime risk of future imaging-related cancers by 62%. The research was published...
Results from a multicenter phase II study of patients with locally advanced HER2-positive breast cancer who receive targeted therapy with trastuzumab (Herceptin) and lapatinib (Tykerb) “support the hypothesis that selected patients with HER2-positive tumors may not need...
A large randomized phase II study, GALAXY-1, found that a novel heat shock protein (Hsp) 90 inhibitor, ganetespib, when combined with docetaxel in second-line therapy, leads to longer overall survival compared to standard second-line docetaxel alone in patients with advanced lung adenocarcinoma...
A genomic profiling study of African American women with breast cancer found that about one in five carries an inherited abnormality in at least 1 of 18 genes associated with breast cancer susceptibility. Such mutations were more prevalent among women with aggressive triple-negative breast cancer,...
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On May 29, 2013, trametinib (Mekinist) was...
The addition of everolimus (Afinitor), an mTOR inhibitor, to trastuzumab (Herceptin) and vinorelbine significantly extended progression-free survival in women with HER2-positive advanced breast cancer, compared to treatment with placebo plus trastuzumab and vinorelbine, in the phase III BOLERO-3...
When retinoblastoma is diagnosed in racial and ethnic minority children whose families don't have private health insurance, it often takes a more invasive, potentially life-threatening course than in other children, probably because of delays in diagnosis, researchers at Dana-Farber/Children's...
Nearly two-thirds of children receiving stem cell transplants returned to the hospital within 6 months for treatment of unexplained fevers, infections, or other problems, according to a study performed at Dana-Farber/Children’s Hospital Cancer Center in Boston. Children who received donor...
Frozen balls of ice can safely kill cancerous tumors that have spread to the lungs, according to the first prospective multicenter trial of cryoablation. The results were presented on April 14, 2013, at the Society of Interventional Radiology’s 38th Annual Scientific Meeting in New Orleans....
Researchers at Moffitt Cancer Center and colleagues at the University of Florida studied health-care providers to determine the factors associated with disparities in human papillomavirus (HPV) vaccination among girls, ages 9 to 17, from low-income families. They found that physician vaccination...
The American Society of Clinical Oncology announced yesterday that it has completed a prototype of CancerLinQ™, the Society’s groundbreaking health information technology (HIT) initiative to achieve higher quality, higher value cancer care with better outcomes for patients. The...
A new immunoassay that tests for the presence of three biomarkers appears to be a valid screening method for the early detection of malignant kidney cancer, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research....
Men with low-risk prostate cancer who previously had to choose between aggressive treatment, with the potential for significant side effects, and active surveillance, with the risk of disease progression, may have a new option. Focal laser ablation uses precisely targeted heat, delivered through a...
In a significant advance for harnessing the immune system to treat leukemias, researchers at Fred Hutchinson Cancer Research Center have successfully infused large numbers of donor-derived T cells specific for a key antileukemic antigen in order to prolong survival in high-risk and relapsed...
Reporting the results of a phase I clinical trial to test the effectiveness of a new class of drugs to augment standard chemotherapy, a team led by Fred Hutchinson Cancer Research Center scientists found that giving patients high doses of vorinostat (Zolinza) in combination with another round...
Celgene International Sàrl announced on Tuesday that its phase III clinical trial of paclitaxel protein-bound particles for injectable suspension, albumin-bound (nab-paclitaxel, Abaraxane) in combination with gemcitabine in treatment-naive patients with metastatic pancreatic cancer...
Patients receiving high-dose methotrexate (HDMTX) are at risk of developing acute kidney injury (AKI) due to delayed methotrexate clearance. New consensus guidelines aim to help the healthcare team optimize the treatment of AKI due to HDMTX and understand at which time points glucarpidase is most...